LIMN$2.75+9.18%
Liminatus Pharma, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$3.7M
Float & O/S:
Inst Own:
DilutionScan read 11 of Liminatus Pharma, Inc.'s SEC filings and found 10 warrant series, 4 convertibles, 3 S-1 registrations and 6 completed offerings on file for LIMN. The latest dilution event on file is an offering on Jul 2, 2026. Analysis updated Aug 30, 2026.
Signal8 Summary
LIMN
Going-concern warning and delisting risk
Snapshot
Liminatus is a pre-revenue biotech micro-cap in a severe financial crunch. With zero dollars of sales in the last three years and a net loss of $10.2M in FY 2025, the business is burning cash fast.
What's Happening Right Now
- : The company proposed a reverse stock split of up to 1-for-50 to regain compliance with Nasdaq minimum bid price rules.
- : Liminatus completed its acquisition of InnocsAI, issuing 1.6 billion shares of common stock to acquire CAR-T therapy assets.
- : Liminatus raised $1.9 million by inducing warrant holders to exercise at a reduced price, issuing new warrants that require stockholder approval.
- : Nasdaq issued a delisting notice because the company failed to meet market value of listed securities requirements.
- : The company disclosed substantial doubt about its ability to continue as a going concern in its latest quarterly report due to cash constraints.
